PL2865751T3 - Stabilizowana alfa-galaktozydaza i jej zastosowania - Google Patents

Stabilizowana alfa-galaktozydaza i jej zastosowania

Info

Publication number
PL2865751T3
PL2865751T3 PL14195875T PL14195875T PL2865751T3 PL 2865751 T3 PL2865751 T3 PL 2865751T3 PL 14195875 T PL14195875 T PL 14195875T PL 14195875 T PL14195875 T PL 14195875T PL 2865751 T3 PL2865751 T3 PL 2865751T3
Authority
PL
Poland
Prior art keywords
galactosidase
stabilized alpha
stabilized
alpha
Prior art date
Application number
PL14195875T
Other languages
English (en)
Inventor
Avidor Shulman
Ilya Ruderfer
Tehila Ben-Moshe
Talia Shekhter
Yaniv Azulay
Yoseph Shaaltiel
Tali Kizhner
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/en
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of PL2865751T3 publication Critical patent/PL2865751T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
PL14195875T 2010-03-02 2011-03-02 Stabilizowana alfa-galaktozydaza i jej zastosowania PL2865751T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
PCT/IL2010/000956 WO2011061736A1 (en) 2009-11-17 2010-11-17 Alkaline alpha galactosidase for the treatment of fabry disease
US201161434499P 2011-01-20 2011-01-20
US201161434503P 2011-01-20 2011-01-20

Publications (1)

Publication Number Publication Date
PL2865751T3 true PL2865751T3 (pl) 2017-03-31

Family

ID=44121635

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14195875T PL2865751T3 (pl) 2010-03-02 2011-03-02 Stabilizowana alfa-galaktozydaza i jej zastosowania

Country Status (23)

Country Link
EP (3) EP2865751B1 (pl)
JP (2) JP5758920B2 (pl)
KR (1) KR101928403B1 (pl)
CN (1) CN102933707B (pl)
AU (1) AU2011222452B2 (pl)
BR (2) BR112012022029B1 (pl)
CA (1) CA2791461C (pl)
DK (1) DK2865751T3 (pl)
ES (2) ES2708843T3 (pl)
FI (1) FIC20230032I1 (pl)
FR (1) FR23C1041I2 (pl)
HR (1) HRP20200428T1 (pl)
HU (2) HUE030959T2 (pl)
IL (2) IL221741A (pl)
IN (1) IN2012MN02262A (pl)
NL (1) NL301249I2 (pl)
NO (1) NO2023041I1 (pl)
NZ (2) NZ623294A (pl)
PL (1) PL2865751T3 (pl)
SG (2) SG183558A1 (pl)
SI (1) SI2865751T1 (pl)
WO (1) WO2011107990A1 (pl)
ZA (1) ZA201206725B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
JP5758920B2 (ja) * 2010-03-02 2015-08-05 プロタリクス リミテッド 安定化α−ガラクトシダーゼおよびその使用
DK2665814T3 (en) * 2011-01-20 2017-09-11 Protalix Ltd NUCLEIC ACID CONSTRUCTION FOR EXPRESSION OF ALPHA-GALACTOSIDASE IN PLANTS AND PLANT CELLS
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
AU2015370125B2 (en) 2014-12-22 2022-02-03 Codexis, Inc. Human alpha-galactosidase variants
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
WO2016146760A1 (en) 2015-03-17 2016-09-22 Greenovation Biotech Gmbh Glycosylated lysosomal proteins, method of production and uses
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CN110381987A (zh) * 2017-01-05 2019-10-25 波塔力克斯有限公司 使用稳定化α-半乳糖苷酶治疗法布里病的治疗方法
WO2018225623A1 (ja) * 2017-06-07 2018-12-13 天野エンザイム株式会社 ラクターゼ原末及びラクターゼ製剤
JP2022515742A (ja) 2018-12-20 2022-02-22 コデクシス, インコーポレイテッド α-ガラクトシダーゼバリアント
JP2023516301A (ja) * 2020-02-28 2023-04-19 コデクシス, インコーポレイテッド ヒトアルファ-ガラクトシダーゼ変異体
MX2023005235A (es) 2020-11-03 2023-10-16 Protalix Ltd Uricasa modificada y usos de la misma.
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒
CN116254287B (zh) * 2022-11-24 2024-06-04 西北农林科技大学 玉米ZmAGA3基因用于提高植物耐旱性的应用
CN118243646B (zh) * 2024-04-24 2025-01-24 武汉简为医疗科技有限公司 一种乳糖不耐受检测试剂盒及其使用方法
JP7745040B1 (ja) * 2024-06-21 2025-09-26 デンカ株式会社 目的タンパク質の回収方法及び製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (en) 1991-10-03 1993-04-04 Guy Ampleman Glycidyl azide polymer
US6329191B1 (en) * 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
WO1999012959A1 (en) * 1997-09-05 1999-03-18 Altus Biologics Inc. Carbohydrate crosslinked glycoprotein crystals
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
ATE303400T1 (de) * 1999-04-02 2005-09-15 Ajinomoto Kk Vefahren zur herstellung von peptiduntereinheiten aus polymer-proteinen
DK1523548T3 (da) 2002-05-15 2010-05-10 Agricultural Res Org Polynukleotidsekvenser, som koder for alkaliske alfa-galactosidaser, og fremgangsmåder til anvendelse heraf
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
JP5137814B2 (ja) * 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
EP1961816B1 (en) * 2005-11-18 2015-09-02 Tokyo Metropolitan Institute of Medical Science Novel highly functional enzyme having modified substrate-specificity
US20100144008A1 (en) 2006-12-21 2010-06-10 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (en) * 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
BRPI0815324A2 (pt) 2007-08-20 2015-07-14 Protalix Ltd "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
JP5758920B2 (ja) * 2010-03-02 2015-08-05 プロタリクス リミテッド 安定化α−ガラクトシダーゼおよびその使用

Also Published As

Publication number Publication date
BR112012022029B1 (pt) 2022-10-11
JP2013520986A (ja) 2013-06-10
SI2865751T1 (sl) 2017-01-31
KR101928403B1 (ko) 2018-12-14
AU2011222452B2 (en) 2015-09-03
NZ623294A (en) 2015-10-30
NL301249I2 (nl) 2023-12-14
HRP20200428T1 (hr) 2020-06-12
ES2708843T3 (es) 2019-04-11
FR23C1041I2 (fr) 2024-08-02
HK1180720A1 (en) 2013-10-25
ES2606532T3 (es) 2017-03-24
EP3088514A1 (en) 2016-11-02
JP5871999B2 (ja) 2016-03-01
CA2791461A1 (en) 2011-09-09
NO2023041I1 (no) 2023-11-01
DK2865751T3 (en) 2017-01-09
RU2012141651A (ru) 2014-04-10
IL221741A (en) 2017-07-31
IN2012MN02262A (pl) 2015-06-12
EP2865751A1 (en) 2015-04-29
KR20130056216A (ko) 2013-05-29
JP2014237694A (ja) 2014-12-18
HUS2300038I1 (hu) 2023-11-28
FIC20230032I1 (fi) 2023-11-02
NZ602317A (en) 2014-04-30
IL253249A (en) 2019-08-29
BR122014021216A2 (pt) 2021-06-01
CN102933707A (zh) 2013-02-13
EP2865751B1 (en) 2016-09-14
RU2604795C2 (ru) 2016-12-10
IL253249B (en) 2020-08-31
EP2542675B1 (en) 2014-12-17
AU2011222452A1 (en) 2012-09-27
JP5758920B2 (ja) 2015-08-05
HUE030959T2 (en) 2017-06-28
CA2791461C (en) 2019-10-22
FR23C1041I1 (pl) 2023-12-29
NL301249I1 (pl) 2023-11-08
EP2542675A1 (en) 2013-01-09
SG10201502609QA (en) 2015-05-28
SG183558A1 (en) 2012-10-30
WO2011107990A1 (en) 2011-09-09
BR112012022029A2 (pt) 2021-05-18
EP3088514B1 (en) 2018-11-28
ZA201206725B (en) 2013-06-26
CN102933707B (zh) 2015-09-30

Similar Documents

Publication Publication Date Title
HUS2300038I1 (hu) Stabilizált alfa-galaktozidáz és ennek alkalmazásai
IL226904A (en) Inganol-3-acetylates iii and Inganol-3-carbamates
IL249669B (en) Converted 5-fluoro-h1-pyrazolopyridines and their use
SMT201700357T1 (it) Ariltriazoloni legati attraverso bis-arile e loro impiego
GB201012175D0 (en) Procedure and mechanisms
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
IL220939A0 (en) Compounds and methods
EP2523664A4 (en) COMPOUNDS AND METHODS
ZA201208173B (en) Peptices and their use
IL229844B (en) Anti-psgl-1 antibodies and their use
IL220812A0 (en) Compounds and methods
LT2531518T (lt) Oligopeptidiniai dariniai ir jų panaudojimas
SI2605757T1 (sl) Formulacije na osnovi nalbufina in njihove uporabe
EP2523560A4 (en) CONNECTIONS AND METHODS
PL2547464T3 (pl) Układ i układ wentylacyjny
GB201001369D0 (en) Tri-flights and stems
GB2485537B (en) Integral -surface and air- personal transport
GB201001384D0 (en) Light-fitting and associated methods
GB201119443D0 (en) GoWinging Concept and patent
GB201014319D0 (en) Compounds and uses thereof